Cellebrite DI
Cellebrite DI's revenue rose 18.6% to $476 million in fiscal 2025. Its operating margin was 14.0%, down from 14.2% a year earlier. Free cash flow was $160 million, up 29.7%. The diluted share count rose 19.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Cellebrite DI does
Cellebrite is an Israeli software company. Its tools help investigators get data off mobile phones and other digital sources, decode it, analyze it and manage it as evidence. It has built them over nearly 20 years of work on phones, including their hardware, firmware and operating systems.
Its customers are mostly law enforcement agencies, which use the software in cases such as child exploitation, homicide, organized crime, human trafficking and financial crime. Defense and intelligence agencies use it for border security and counter-terrorism. Companies use it for corporate investigations, eDiscovery (collecting digital records for legal cases) and incident response, and to test mobile apps.
Cellebrite sells its software mainly through annual and multi-year subscriptions. It tracks annual recurring revenue, the yearly value of those subscriptions, and says it has seen that figure and customer retention grow. Its results depend on customers renewing and buying more, and on government agencies continuing to buy.
Its biggest risks, as it describes them
- It must keep building new, technically advanced products, or its revenue may suffer.
- Its revenue falls if law enforcement and other government agencies stop buying or using its tools.
- Errors, failures or bugs in its software could hurt its results and growth.
- It licenses technology from third parties and could lose those licenses.
- It faces intense competition and industry consolidation that could add to price pressure.
Income statement
From fiscal 2021 to 2025, earnings per share fell 8.4% a year and net income grew 2.3% a year, as new shares raised the share count by 55% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 146 | 132 | 228 | 294 | 276 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 1.5x | 1.4x | 1.7x | 1.9x | 1.6x |
| Quick ratio | 1.4x | 1.4x | 1.6x | 1.9x | 1.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 49.9% | 54.2% | 52.3% |
| Altman Z'' | 3.29 | 3.36 | 2.73 |
| Accruals ratio | −39.1% | −67.9% | −11.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Cellebrite DI side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cellebrite DI | FY25 | 18.6% | 14.0% | 33.7% | — | — | — | |
| Strategy | FY25 | 3.0% | −1,140.8% | −15.8% | −11.4% | — | 4 | Compare |
| Life360 | FY25 | 31.8% | 3.9% | 17.7% | 6.7% | −5.7x | 5 | Compare |
| Xunlei | FY25 | 42.5% | 1.4% | 5.9% | 1.1% | −15.2x | 5 | Compare |
| PagerDuty | FY26 | 5.4% | 1.2% | 22.7% | 4.7% | −2.6x | 7 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 172 | 195 | 246 | 271 | 325 | 401 | 476 |
| Revenue growth | — | 13.4% | 26.3% | 9.9% | 20.1% | 23.4% | 18.6% |
| Gross profit | 136 | 157 | 204 | 220 | 272 | 339 | 400 |
| Research and development | 47 | 54 | 66 | 81 | 84 | 98 | 114 |
| Operating income | −2 | 9 | 14 | 1 | 33 | 57 | 66 |
| Net income | −2 | 6 | 71 | 121 | −81 | −283 | 78 |
| Diluted EPS (US$) | −0.08 | −0.08 | 0.44 | 0.59 | −0.43 | −1.35 | 0.31 |
| Diluted shares (millions) | 122 | 124 | 162 | 195 | 190 | 210 | 250 |
| Cash flow | |||||||
| Cash from operations | 16 | 66 | 36 | 21 | 102 | 132 | 174 |
| Capital expenditure | 6 | 6 | 5 | 7 | 5 | 9 | 13 |
| Free cash flow | 10 | 60 | 31 | 14 | 97 | 124 | 160 |
| Dividends paid | 25 | 10 | 100 | 0 | 0 | 0 | 0 |
| Share buybacks | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 15 | 20 | 0 | 0 | 3 | 148 |
| Stock-based compensation | 13 | 7 | 6 | 14 | 19 | 31 | 45 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 82 | 134 | 146 | 132 | 228 | 294 | 276 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 364 | 340 | 403 | 533 | 691 | 939 |
| Total liabilities | — | 199 | 413 | 329 | 499 | 354 | 454 |
| Shareholders' equity | 59 | 64 | −73 | 74 | 34 | 336 | 484 |
| Margins and ratios | |||||||
| Gross margin | 79.2% | 80.6% | 82.7% | 81.2% | 83.6% | 84.4% | 84.2% |
| Operating margin | −0.9% | 4.7% | 5.6% | 0.4% | 10.2% | 14.2% | 14.0% |
| Net margin | −1.1% | 3.0% | 29.0% | 44.6% | −24.9% | −70.5% | 16.5% |
| Free cash flow margin | 5.8% | 30.9% | 12.6% | 5.0% | 29.8% | 30.8% | 33.7% |
| Rule of 40 (growth + FCF margin) | — | 44.4% | 38.9% | 15.0% | 49.9% | 54.2% | 52.3% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | −150.1% | −152.9% | 19.1% |
| Return on assets | — | — | 20.3% | 32.5% | −17.3% | −46.3% | 9.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — |